Publications by authors named "Luis Perez-Tosar"
Article Synopsis
- Immunogenicity guidance in the biopharmaceutical industry has evolved significantly over the past 20 years due to initial negative reactions with erythropoietin, leading to stringent practices for all biotherapeutic drugs.
- A recent workshop by the European Bioanalysis Forum highlighted the need to reassess current immunogenicity testing methods, drawing from two decades of experience to suggest more relevant approaches.
- The proposed new paradigm encourages a context-based assessment of immunogenicity risk, viewing it as a pharmacodynamic biomarker, which aims to streamline testing strategies and better allocate resources for patient benefit.
CD8+ T cells have the potential to control HSV-2 infection. However, limited information has been available on CD8+ T cell epitopes or the functionality of antigen specific T cells during infection or following immunization with experimental vaccines. Peptide panels from HSV-2 proteins ICP27, VP22 and VP13/14 were selected from in silico predictions of binding to human HLA-A*0201 and mouse H-2Kd, Ld and Dd molecules.
View Article and Find Full Text PDFAntisense oligonucleotides (ASOs) and small interfering RNA (siRNA) promise specific correction of disease-causing gene expression. Therapeutic implementation, however, has been forestalled by poor delivery to the appropriate tissue, cell type, and subcellular compartment. Topical administration is considered to circumvent these issues.
View Article and Find Full Text PDF